keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Inavolisib (GDC-0077) is an orally available and selective inhibitor of PI3Kα (IC50=0.038 nM). Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 46,500 |
5 mg | 在庫あり | ¥ 95,000 |
10 mg | 在庫あり | ¥ 155,000 |
25 mg | 在庫あり | ¥ 223,500 |
50 mg | 在庫あり | ¥ 328,500 |
100 mg | 在庫あり | ¥ 443,000 |
200 mg | 在庫あり | ¥ 594,500 |
500 mg | 在庫あり | ¥ 888,500 |
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 97,500 |
説明 | Inavolisib (GDC-0077) is an orally available and selective inhibitor of PI3Kα (IC50=0.038 nM). Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. |
ターゲット&IC50 | PI3Kα:0.038 nM |
In vitro | Inavolisib is >300-fold more selective for PI3Kα over the other class I PI3K isoforms (β, δ, and γ). Inavolisib is >2000-fold more selective over PIK family members. Inavolisib selectively degrades mutant PI3Kα in a proteasome-dependent fashion. When compared to PIK3CA wild-type cells, Inavolisib results in a reduction of PI3K pathway activity biomarkers such as pAKT and pPRAS40, inhibition of cell proliferation. Inavolisib also increased apoptosis in human PIK3CA-mutant breast cancer cell lines to a greater extent [1]. |
In vivo | In patient-derived PIK3CA-mutant breast cancer xenograft models, Inavolisib (p.o.) causes tumor regressions, induction of apoptosis, and a reduction of pAKT, pPRAS40, and pS6RP in a dose-dependent fashion [1]. |
別名 | GDC-0077, RG6114 |
分子量 | 407.37 |
分子式 | C18H19F2N5O4 |
CAS No. | 2060571-02-8 |
keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (245.48 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Inavolisib 2060571-02-8 Apoptosis PI3K/Akt/mTOR signaling PI3K GDC-0077 GDC0077 Phosphoinositide 3-kinase Inhibitor RG6114 RG-6114 GDC 0077 inhibit RG 6114 inhibitor